Cognition Therapeutics Hosts Investor Webcast To Discuss Results From Phase 2 SHINE Study Of CT1812 In Mild-to-Moderate Alzheimer's Disease At 8:30am ET On Monday July 29, 2024
Portfolio Pulse from Benzinga Newsdesk
Cognition Therapeutics, Inc. (NASDAQ:CGTX) will host an investor webcast on July 29, 2024, to discuss results from the Phase 2 SHINE study of CT1812 in mild-to-moderate Alzheimer's disease. The webcast will cover clinical efficacy, safety, and biomarker findings. Results will also be presented at the Alzheimer's Association's International Conference.
July 26, 2024 | 8:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cognition Therapeutics will discuss Phase 2 SHINE study results for CT1812 in a webcast on July 29, 2024. The webcast will cover clinical efficacy, safety, and biomarker findings, which will also be presented at the Alzheimer's Association's International Conference.
The webcast and conference presentation will provide important updates on the clinical efficacy, safety, and biomarker findings of CT1812, which could positively impact investor sentiment and the stock price of CGTX in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100